Truncation of Macrophage-derived Chemokine by CD26/ Dipeptidyl-Peptidase IV beyond Its Predicted Cleavage Site Affects Chemotactic Activity and CC Chemokine Receptor 4 Interaction

Paul Proost, Sofie Struyf, Dominique Schols, Ghislain Opdenakker, Silvano Sozzani, Paola Allavena, Alberto Mantovani, Koen Augustyns, Gunther Bal, Achiel Haemers,

Journal of Biological Chemistry · 1999 · 153 citations · 29 references

DOIFull text

Open access

Concepts

Abstract

The serine protease CD26/dipeptidyl-peptidase IV (CD26/DPP IV) and chemokines are known key players in immunological processes. Surprisingly, CD26/DPP IV not only removed the expected Gly1-Pro2 dipeptide from the NH2 terminus of macrophage-derived chemokine (MDC) but subsequently also the Tyr3-Gly4 dipeptide, generating MDC(5–69). This second cleavage after a Gly residue demonstrated that the substrate specificity of this protease is less restricted than anticipated. The unusual processing of MDC by CD26/DPP IV was confirmed on the synthetic peptides GPYGANMED (MDC(1–9)) and YGANMED (MDC(3–9)). Compared with intact MDC(1–69), CD26/DPP IV-processed MDC(5–69) had reduced chemotactic activity on lymphocytes and monocyte-derived dendritic cells, showed impaired mobilization of intracellular Ca2+ through CC chemokine receptor 4 (CCR4), and was unable to desensitize for MDC-induced Ca2+-responses in CCR4 transfectants. However, MDC(5–69) remained equally chemotactic as intact MDC(1–69) on monocytes. In contrast to the reduced binding to lymphocytes and CCR4 transfectants, MDC(5–69) retained its binding properties to monocytes and its anti-HIV-1 activity. Thus, NH2-terminal truncation of MDC by CD26/DPP IV has profound biological consequences and may be an important regulatory mechanism during the migration of Th2 lymphocytes and dendritic cells to germinal centers and to sites of inflammation. The serine protease CD26/dipeptidyl-peptidase IV (CD26/DPP IV) and chemokines are known key players in immunological processes. Surprisingly, CD26/DPP IV not only removed the expected Gly1-Pro2 dipeptide from the NH2 terminus of macrophage-derived chemokine (MDC) but subsequently also the Tyr3-Gly4 dipeptide, generating MDC(5–69). This second cleavage after a Gly residue demonstrated that the substrate specificity of this protease is less restricted than anticipated. The unusual processing of MDC by CD26/DPP IV was confirmed on the synthetic peptides GPYGANMED (MDC(1–9)) and YGANMED (MDC(3–9)). Compared with intact MDC(1–69), CD26/DPP IV-processed MDC(5–69) had reduced chemotactic activity on lymphocytes and monocyte-derived dendritic cells, showed impaired mobilization of intracellular Ca2+ through CC chemokine receptor 4 (CCR4), and was unable to desensitize for MDC-induced Ca2+-responses in CCR4 transfectants. However, MDC(5–69) remained equally chemotactic as intact MDC(1–69) on monocytes. In contrast to the reduced binding to lymphocytes and CCR4 transfectants, MDC(5–69) retained its binding properties to monocytes and its anti-HIV-1 activity. Thus, NH2-terminal truncation of MDC by CD26/DPP IV has profound biological consequences and may be an important regulatory mechanism during the migration of Th2 lymphocytes and dendritic cells to germinal centers and to sites of inflammation. CD26/dipeptidyl-peptidase IV (CD26/DPP IV 1The abbreviations used are: CCR or CXCR, CC or CXC chemokine receptor; CD26/DPP IV, dipeptidyl-peptidase IV; GCP-2, granulocyte chemotactic protein-2; IL, interleukin; MDC, macrophage-derived chemokine; RANTES, regulated on activation normal T cell expressed and secreted; HPLC, high performance liquid chromatography; SDF-1, stromal cell-derived factor-1; HIV-1, human immundeficiency virus-1; PBMC, peripheral blood-derived mononuclear cells.; EC 3.4.14.5) is a 110-kDa glycoprotein expressed on the membrane of a variety of cells including epithelial and endothelial cells. Moreover, its expression is up-regulated on activated T cells (1von Bonin A. Hühn J. Fleisher B. Immunol. Rev. 1998; 161: 43-53Crossref PubMed Scopus (132) Google Scholar, 2Morimoto C. Schlossman S.F. Immunol. Rev. 1998; 161: 55-70Crossref PubMed Scopus (372) Google Scholar, 3Yaron A. Naider F. Crit. Rev. Biochem. Mol. Biol. 1993; 28: 31-81Crossref PubMed Scopus (523) Google Scholar). The proteolytic activity of CD26/DPP IV is located in the extracellular domain of the protein, which also occurs in a soluble active form in plasma. CD26/DPP IV has a unique specificity compared with other exopeptidases. It is known to cleave dipeptides from the NH2 terminus of peptides with a penultimate Pro, Hyp, or Ala residue. The penultimate NH2-terminal Pro is present in a number of cytokines (e.g. interleukin-1β (IL-1β), IL-2, IL-5, IL-6, and IL-10), growth factors (e.g. insulin-like growth factor 1, granulocyte colony-stimulating factor, and growth hormone), neuro- and vasoactive peptides (e.g. neuropeptide Y, peptide YY, and substance P) and chemokines (e.g. stromal cell-derived factor-1α (SDF-1α) and RANTES). This Pro residue protects these molecules from degradation by most aminopeptidases (4Vanhoof G. Goossens F. De Meester I. Hendriks D. Scharpé S. FASEB J. 1995; 9: 736-744Crossref PubMed Scopus (384) Google Scholar). Some short peptides, including substance P and gastrin-releasing peptide have been known for some time as effective substrates for CD26/DPP IV (3Yaron A. Naider F. Crit. Rev. Biochem. Mol. Biol. 1993; 28: 31-81Crossref PubMed Scopus (523) Google Scholar). In contrast, none of the intact cytokines with a penultimate Pro has been identified as a CD26/DPP IV substrate although smaller peptides containing their NH2-terminal sequences were cleaved (5Hoffmann T. Faust J. Neubert K. Ansorge S. FEBS Lett. 1993; 336: 61-64Crossref PubMed Scopus (116) Google Scholar). A number of observations indicate that CD26/DPP IV plays an important role in immunology, in particular during T cell activation and proliferation (1von Bonin A. Hühn J. Fleisher B. Immunol. Rev. 1998; 161: 43-53Crossref PubMed Scopus (132) Google Scholar, 2Morimoto C. Schlossman S.F. Immunol. Rev. 1998; 161: 55-70Crossref PubMed Scopus (372) Google Scholar). The involvement of the enzymatic activity in the immunoregulatory function of CD26/DPP IV is demonstrated under several circumstances. These include the in vitro normalization of impaired responses to recall antigens by the addition of soluble CD26/DPP IV (6Tanaka T. Duke-Cohan J. Kameoka J. Yaron A. Lee I. Schlossman S.F. Morimoto C. Proc. Natl. Acad. Sci. U. S. A. 1994; 91: 3082-3086Crossref PubMed Scopus (129) Google Scholar, 7Schmitz T. Underwood R. Khiroya R. Bachovchin W. Huber B. J. Clin. Invest. 1996; 97: 1545-1549Crossref PubMed Scopus (26) Google Scholar) and the in vivo suppression of immune activation upon alloantigen challenge by specific CD26/DPP IV inhibitors (8Korom S. De Meester I. Stadlbauer T.H.W. Chandraker A. Schaub M. Sayegh M.H. Belyaev A. Haemers A. Scharpé S. Kupiec-Weglinski J.W. Transplantation. 1997; 63: 1495-1500Crossref PubMed Scopus (95) Google Scholar). Recently, CD26/DPP IV has been shown to process the NH2 terminus of a number of chemokines including RANTES, granulocyte chemotactic protein-2 (GCP-2), and SDF-1, generating naturally occurring truncated molecules with a significantly altered biological activity (9Proost P. De Meester I. Schols D. Struyf S. Lambeir A.-M. Wuyts A. Opdenakker G. De Clercq E. Scharpé S. Van Damme J. J. Biol. Chem. 1998; 273: 7222-7227Abstract Full Text Full Text PDF PubMed Scopus (238) Google Scholar, 10Oravecz T. Pall M. Roderiquez G. Gorrell M.D. Ditto M. Nguyen N.Y. Boykins R. Unsworth E. Norcross M.A. J. Exp. Med. 1997; 186: 1865-1872Crossref PubMed Scopus (318) Google Scholar, 11Proost P. Struyf S. Schols S. Durinx C. Wuyts A. Lenaerts J.-P. De Clercq E. De Meester I. Van Damme J. FEBS Lett. 1998; 432: 73-76Crossref PubMed Scopus (180) Google Scholar, 12Shioda T. Kato H. Ohnishi Y. Tashiro K. Ikegawa M. Nakayama E.E. Hu H. Kato A. Sakai Y. Liu H. Honjo T. Nomoto A. Iwamoto A. Morimoto C. Nagai Y. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 6331-6336Crossref PubMed Scopus (161) Google Scholar). Indeed, truncation of RANTES by CD26/DPP IV into RANTES(3–68) generated a chemotaxis antagonist with enhanced anti-HIV-1 activity against macrophage-tropic (M-tropic) HIV-1 strains. Incubation of SDF-1 with CD26/DPP IV drastically reduced the chemotactic activity of this chemokine but also reduced its anti-HIV-1 activity against T cell-tropic (T-tropic) HIV-1 strains. The recently identified CC chemokine macrophage-derived chemokine (MDC), also designated stimulated T cell chemotactic protein-1 (STCP-1), binds to CC chemokine receptor 4 (CCR4). The MDC cDNA was one of the most abundant sequences identified in a macrophage library. MDC is synthesized by macrophages and dendritic cells and is highly expressed in the thymus (13Godiska R. Chantry D. Raport C.J. Sozzani S. Allavena P. Leviten D. Mantovani A. Gray P.W. J. Exp. Med. 1997; 185: 1595-1604Crossref PubMed Scopus (428) Google Scholar, 14Imai T. Chantry D. Raport C.J. Wood C.L. Nishimura M. Godiska R. Yoshie O. Gray P.W. J. Biol. Chem. 1998; 273: 1764-1768Abstract Full Text Full Text PDF PubMed Scopus (321) Google Scholar, 15Chang M.-S. McNinch J. Elias III, C. Manthey C.L. Grosshans D. Meng T. Boone T. Andrew D.P. J. Biol. Chem. 1997; 272: 25229-25237Abstract Full Text Full Text PDF PubMed Scopus (88) Google Scholar, 16Chantry D. DeMaggio A.J. Brammer H. Raport C.J. Wood C.L. Schweickart V.L. Epp A. Smith A. Stine J.T. Walton K. Tjoelker L. Godiska R. Gray P.W. J. Leukocyte Biol. 1998; 64: 49-54Crossref PubMed Scopus (37) Google Scholar). NH2-terminally truncated forms of natural MDC were isolated from a CD8+ T cell clone and have been reported to inhibit HIV-1 infection (17Pal R. A. J. M. 1997; in PubMed Scopus Google Scholar). that MDC is a CD26/DPP IV Surprisingly, the an dipeptide from the MDC NH2 terminus that the substrate specificity of this dipeptidyl-peptidase is less restricted than anticipated. In this truncation the receptor and chemotactic activity of synthetic MDC were from and NH2-terminal chemokine or YGANMED or or and or were synthesized an peptide The peptides were by and on an CD26/DPP IV was from and to by Meester I. G. Lambeir A.-M. Scharpé S. J. Immunol. 1996; PubMed Scopus Google Scholar). CD26/DPP IV, membrane and was from and and as A.-M. P. G. K. B. Van J. De Meester I. Scharpé S. 1997; PubMed Scopus Google Scholar). peripheral blood-derived mononuclear cells were from and isolated by and P. Wuyts A. R. Lenaerts J.-P. W. Van Damme J. 1996; Scopus Google Scholar). were from the mononuclear cell with to dendritic cells were as (13Godiska R. Chantry D. Raport C.J. Sozzani S. Allavena P. Leviten D. Mantovani A. Gray P.W. J. Exp. Med. 1997; 185: 1595-1604Crossref PubMed Scopus (428) Google Scholar). cells were in with and cells with and CCR4 were in and H. Liu R. W. S. D. M. P. S. 1996; PubMed Scopus Google Scholar). MDC was with or soluble CD26/DPP IV and by as (9Proost P. De Meester I. Schols D. Struyf S. Lambeir A.-M. Wuyts A. Opdenakker G. De Clercq E. Scharpé S. Van Damme J. J. Biol. Chem. 1998; 273: 7222-7227Abstract Full Text Full Text PDF PubMed Scopus (238) Google Scholar, 11Proost P. Struyf S. Schols S. Durinx C. Wuyts A. Lenaerts J.-P. De Clercq E. De Meester I. Van Damme J. FEBS Lett. 1998; 432: 73-76Crossref PubMed Scopus (180) Google Scholar). NH2-terminal truncation was after or on of MDC by degradation on a of the synthetic MDC peptides was by The synthetic peptides were with CD26/DPP IV in containing time were in of of in was under were on a and of and of the the was with as a and with intact substrates and peptide degradation was by The peptides were with CD26/DPP IV in containing time were and in of in were to an and the peptides were in a and of MDC were from the the of CD26/DPP IV for the peptides and the synthetic substrate were CD26/DPP IV enzymatic activity was as a The was and the was and The of CD26/DPP IV and and were in The is as the of peptide to CD26/DPP IV activity to of the the specificity of the the was by the specific Meester I. Belyaev A. Lambeir A.-M. De Van Haemers A. Scharpé S. Biochem. 1997; PubMed Scopus (26) Google Scholar) the of the The chemotactic activity of chemokines for cells, or monocyte-derived dendritic cells was in chemotaxis as P. Struyf S. Schols S. Durinx C. Wuyts A. Lenaerts J.-P. De Clercq E. De Meester I. Van Damme J. FEBS Lett. 1998; 432: 73-76Crossref PubMed Scopus (180) Google Scholar, R. Chantry D. Raport C.J. Sozzani S. Allavena P. Leviten D. Mantovani A. Gray P.W. J. Exp. Med. 1997; 185: 1595-1604Crossref PubMed Scopus (428) Google Scholar). cells were to for 4 through P. Struyf S. Schols S. Durinx C. Wuyts A. Lenaerts J.-P. De Clercq E. De Meester I. Van Damme J. FEBS Lett. 1998; 432: 73-76Crossref PubMed Scopus (180) Google Scholar). monocytes and monocyte-derived dendritic cells chemotaxis through was after (13Godiska R. Chantry D. Raport C.J. Sozzani S. Allavena P. Leviten D. Mantovani A. Gray P.W. J. Exp. Med. 1997; 185: 1595-1604Crossref PubMed Scopus (428) Google Scholar). were cells were and and are expressed as chemotactic to the number of cells to the the number of cells that to The intracellular Ca2+ were the P. Struyf S. Schols S. Durinx C. Wuyts A. Lenaerts J.-P. De Clercq E. De Meester I. Van Damme J. FEBS Lett. 1998; 432: 73-76Crossref PubMed Scopus (180) Google Scholar) and were from the G. M. J. Biol. Chem. Full Text PDF PubMed Scopus Google Scholar). cells were stimulated with intact or CD26/DPP MDC and with intact MDC a that a in after with for MDC binding was on PBMC, monocytes or lymphocytes or cells as D. P. Struyf S. Wuyts A. De Meester I. Scharpé S. Van Damme J. De Clercq E. 1998; PubMed Scopus Google Scholar). or cell cells were for 4 with and of were and with of with and the present on the cells was in a from were stimulated with for infection with the HIV-1 through the of and The activated cells were with to and of intact or CD26/DPP MDC were P. Struyf S. Schols S. Durinx C. Wuyts A. Lenaerts J.-P. De Clercq E. De Meester I. Van Damme J. FEBS Lett. 1998; 432: 73-76Crossref PubMed Scopus (180) Google Scholar). were in the of and after cell were HIV-1 was by a and synthetic MDC(1–69) were with CD26/DPP Incubation of synthetic MDC(1–69) with natural intact CD26/DPP IV for in the of NH2-terminal MDC(5–69) This was confirmed with MDC(1–69) with the soluble form of the However, a of was also of with or soluble CD26/DPP IV also in into MDC(5–69). of with the of MDC(5–69) of the intact truncation of MDC by CD26/DPP MDC or of of in of the by with CD26/DPP IV of which the biological activity was with the was removed by the with membrane CD26/DPP IV but including the was for 1, or with natural soluble or CD26/DPP IV to NH2-terminal sequences after by or after on and are MDC or of in of the by Incubation with CD26/DPP IV of which the biological activity was with the was removed by the Incubation with membrane CD26/DPP IV but including the in a MDC was for 1, or with natural soluble or CD26/DPP IV to NH2-terminal sequences after by or after on and are the of the in the of the an important on the the NH2-terminal peptides and were The of these peptides with the of a used CD26/DPP IV was and the for this and the were for cleavage of compared with In was a less for CD26/DPP compared with by CD26/DPP IV was also by of NH2 of the peptides from with CD26/DPP The NH2-terminal of RANTES and MDC were cleaved by CD26/DPP IV into and that CD26/DPP IV is for the of the was in to inhibit In a in the of the specific the of was CD26/DPP IV was to and generating NH2 during the time compared with not on the in cleavage the NH2 and were with CD26/DPP IV and the peptides, time were by the was cleaved of the generated is into the the and with of this peptide is after In of MDC(1–69) and were with CD26/DPP IV for on and the of the forms of MDC were by degradation The of this short that dipeptides are and removed from the MDC and that the in is compared with the second MDC was compared with intact MDC to the migration of cells, peripheral monocytes and monocyte-derived dendritic cells. cells MDC(1–69) was chemotactic from on of MDC(5–69) were to an chemotactic In contrast, intact MDC and CD26/DPP MDC(5–69) were equally to chemotaxis of chemokine cell CD26/DPP IV of MDC also in reduced chemotactic on monocyte-derived dendritic cells MDC significantly in vitro chemotaxis of dendritic cells MDC(5–69) remained to the altered chemotactic was MDC through and binding to the only known MDC was by of MDC with CD26/DPP Indeed, intact MDC(1–69) a in cells effective of MDC(5–69) was unable to in contrast to intact MDC, of MDC(5–69) not desensitize for a by of intact Compared with MDC(1–69), the of MDC(5–69) to for binding to CCR4 was of MDC(5–69) for binding of MDC(1–69) was on cells 4 on 4 and on lymphocytes However, on monocytes by with MDC(5–69) as as intact MDC for cells with and CCR4 peripheral mononuclear cells lymphocytes or monocytes by cell were with in and of MDC(1–69) or MDC(5–69) are expressed as the of specific binding of to on cells of with with MDC has been reported to have activity against and HIV-1 (17Pal R. A. J. M. 1997; in PubMed Scopus Google Scholar). CD26/DPP MDC and intact MDC had anti-HIV-1 activity against infection of with the of HIV-1 infection was not the was in to of intact or CD26/DPP CD26/DPP IV is in the in vivo of a number of natural peptides containing a penultimate Pro (e.g. or Ala (e.g. (4Vanhoof G. Goossens F. De Meester I. Hendriks D. Scharpé S. FASEB J. 1995; 9: 736-744Crossref PubMed Scopus (384) Google Scholar, R. B. W. J. Biochem. 1993; PubMed Scopus Google Scholar). and in contrast to a number of which have a penultimate Pro their NH2 some chemokines have been identified as substrates for this protease (9Proost P. De Meester I. Schols D. Struyf S. Lambeir A.-M. Wuyts A. Opdenakker G. De Clercq E. Scharpé S. Van Damme J. J. Biol. Chem. 1998; 273: 7222-7227Abstract Full Text Full Text PDF PubMed Scopus (238) Google Scholar, 10Oravecz T. Pall M. Roderiquez G. Gorrell M.D. Ditto M. Nguyen N.Y. Boykins R. Unsworth E. Norcross M.A. J. Exp. Med. 1997; 186: 1865-1872Crossref PubMed Scopus (318) Google Scholar, 11Proost P. Struyf S. Schols S. Durinx C. Wuyts A. Lenaerts J.-P. De Clercq E. De Meester I. Van Damme J. FEBS Lett. 1998; 432: 73-76Crossref PubMed Scopus (180) Google Scholar, 12Shioda T. Kato H. Ohnishi Y. Tashiro K. Ikegawa M. Nakayama E.E. Hu H. Kato A. Sakai Y. Liu H. Honjo T. Nomoto A. Iwamoto A. Morimoto C. Nagai Y. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 6331-6336Crossref PubMed Scopus (161) Google Scholar). the chemotactic and were to be from CD26/DPP by an NH2-terminal (9Proost P. De Meester I. Schols D. Struyf S. Lambeir A.-M. Wuyts A. Opdenakker G. De Clercq E. Scharpé S. Van Damme J. J. Biol. Chem. 1998; 273: 7222-7227Abstract Full Text Full Text PDF PubMed Scopus (238) Google Scholar, E. P. Van I. Struyf S. M. De Meester I. D. Van Damme J. Opdenakker G. 1998; PubMed Scopus Google Scholar). on the MDC containing a penultimate Pro, and on the that natural NH2-terminally truncated MDC forms have been isolated (17Pal R. A. J. M. 1997; in PubMed Scopus Google the CC chemokine MDC was as a substrate for CD26/DPP and synthetic MDC(1–69) were with the CD26/DPP IV to MDC was cleaved after the penultimate Pro as shown for the chemokines RANTES, and (9Proost P. De Meester I. Schols D. Struyf S. Lambeir A.-M. Wuyts A. Opdenakker G. De Clercq E. Scharpé S. Van Damme J. J. Biol. Chem. 1998; 273: 7222-7227Abstract Full Text Full Text PDF PubMed Scopus (238) Google Scholar, 10Oravecz T. Pall M. Roderiquez G. Gorrell M.D. Ditto M. Nguyen N.Y. Boykins R. Unsworth E. Norcross M.A. J. Exp. Med. 1997; 186: 1865-1872Crossref PubMed Scopus (318) Google Scholar, 11Proost P. Struyf S. Schols S. Durinx C. Wuyts A. Lenaerts J.-P. De Clercq E. De Meester I. Van Damme J. FEBS Lett. 1998; 432: 73-76Crossref PubMed Scopus (180) Google Scholar, 12Shioda T. Kato H. Ohnishi Y. Tashiro K. Ikegawa M. Nakayama E.E. Hu H. Kato A. Sakai Y. Liu H. Honjo T. Nomoto A. Iwamoto A. Morimoto C. Nagai Y. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 6331-6336Crossref PubMed Scopus (161) Google Scholar). It was that of MDC(1–69) with CD26/DPP IV in the of NH2-terminal MDC(5–69) of the A of was also that this form is generated as an The of into MDC(5–69) was by the specific CD26/DPP IV This confirmed that the of MDC(5–69) was specific for CD26/DPP IV and that the cleavage the of the NH2-terminal dipeptides The cleavage after is on on the specificity of this protease (1von Bonin A. Hühn J. Fleisher B. Immunol. Rev. 1998; 161: 43-53Crossref PubMed Scopus (132) Google Scholar, 2Morimoto C. Schlossman S.F. Immunol. Rev. 1998; 161: 55-70Crossref PubMed Scopus (372) Google Scholar, 3Yaron A. Naider F. Crit. Rev. Biochem. Mol. Biol. 1993; 28: 31-81Crossref PubMed Scopus (523) Google Scholar, G. Goossens F. De Meester I. Hendriks D. Scharpé S. FASEB J. 1995; 9: 736-744Crossref PubMed Scopus (384) Google Scholar, J. T. M. E. PubMed Scopus Google Scholar). by other aminopeptidases in the natural or soluble CD26/DPP IV was to be truncation of RANTES, GCP-2, or was with the CD26/DPP IV (9Proost P. De Meester I. Schols D. Struyf S. Lambeir A.-M. Wuyts A. Opdenakker G. De Clercq E. Scharpé S. Van Damme J. J. Biol. Chem. 1998; 273: 7222-7227Abstract Full Text Full Text PDF PubMed Scopus (238) Google Scholar, 11Proost P. Struyf S. Schols S. Durinx C. Wuyts A. Lenaerts J.-P. De Clercq E. De Meester I. Van Damme J. FEBS Lett. 1998; 432: 73-76Crossref PubMed Scopus (180) Google Scholar). of the of the cleavage of intact MDC and of NH2-terminal by CD26/DPP IV confirmed that dipeptides were subsequently removed and that the compared with the second this is the on the CD26/DPP of an NH2-terminal dipeptide from a natural A by J. T. M. E. PubMed Scopus Google Scholar) on growth and synthetic that the of a Gly or as the penultimate residue degradation by CD26/DPP IV although a compared with the natural containing a penultimate In contrast, the synthetic peptide with an Ala to Gly was to cleavage by CD26/DPP IV D. A. M. W. M. De L. S. 1997; PubMed Scopus Google Scholar). the not the of by CD26/DPP IV, which that is not from although the dipeptide was from the synthetic growth with a penultimate J. T. M. E. PubMed Scopus Google Scholar). It was for other that the less the residue to cleavage is the the substrate the The of the the with which CD26/DPP IV dipeptides from substrates with an unusual penultimate residue B. of Google Scholar). The CC chemokine MDC is chemotactic for Th2 dendritic cells, and natural cells (13Godiska R. Chantry D. Raport C.J. Sozzani S. Allavena P. Leviten D. Mantovani A. Gray P.W. J. Exp. Med. 1997; 185: 1595-1604Crossref PubMed Scopus (428) Google Scholar, 15Chang M.-S. McNinch J. Elias III, C. Manthey C.L. Grosshans D. Meng T. Boone T. Andrew D.P. J. Biol. Chem. 1997; 272: 25229-25237Abstract Full Text Full Text PDF PubMed Scopus (88) Google Scholar, R. G. D. R. A. Sozzani S. Allavena P. Gray Mantovani A. F. J. Exp. Med. 1998; PubMed Scopus Google Scholar). intact MDC and MDC(5–69) were equally chemotactic In contrast, cleavage of MDC into MDC(5–69) in reduced chemotactic activity on and dendritic cells. A of the chemotactic activity has been for the chemokines RANTES and CD26/DPP IV processing had on the chemotactic activity of of the dipeptide from the NH2 terminus of and RANTES the of chemotactic activity on lymphocytes P. Struyf S. Schols S. Durinx C. Wuyts A. Lenaerts J.-P. De Clercq E. De Meester I. Van Damme J. FEBS Lett. 1998; 432: 73-76Crossref PubMed Scopus (180) Google Scholar, 12Shioda T. Kato H. Ohnishi Y. Tashiro K. Ikegawa M. Nakayama E.E. Hu H. Kato A. Sakai Y. Liu H. Honjo T. Nomoto A. Iwamoto A. Morimoto C. Nagai Y. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 6331-6336Crossref PubMed Scopus (161) Google Scholar) and monocytes or S. De Meester I. Scharpé S. Lenaerts J.-P. P. P. Van Damme J. J. Immunol. 1998; 28: PubMed Scopus Google The reduced binding of MDC(5–69) to CCR4 and the reduced of CD26/DPP MDC through this receptor the chemotactic activity on lymphocytes and dendritic cells. Moreover, MDC(5–69) not desensitize for a by the intact In with the chemotaxis on CD26/DPP IV processing had on the binding properties of MDC to monocytes. The activity of MDC against HIV-1 infection of with a also remained In this is to that MDC(5–69) and of MDC cleavage by CD26/DPP IV) are the most abundant MDC forms that were from CD8+ T cells on their activity against the HIV-1 (17Pal R. A. J. M. 1997; in PubMed Scopus Google Scholar). However, with the MDC indicate that NH2-terminal truncation of MDC the several the or of anti-HIV-1 activity for this binding to and through its receptor were also However, this in contrast to MDC, most of its activity against HIV-1 P. Struyf S. Schols S. Durinx C. Wuyts A. Lenaerts J.-P. De Clercq E. De Meester I. Van Damme J. FEBS Lett. 1998; 432: 73-76Crossref PubMed Scopus (180) Google Scholar, 12Shioda T. Kato H. Ohnishi Y. Tashiro K. Ikegawa M. Nakayama E.E. Hu H. Kato A. Sakai Y. Liu H. Honjo T. Nomoto A. Iwamoto A. Morimoto C. Nagai Y. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 6331-6336Crossref PubMed Scopus (161) Google Scholar, P. K. A. F. M. I. J. 1997; PubMed Scopus Google Scholar). RANTES(3–68) its properties through and T. Pall M. Roderiquez G. Gorrell M.D. Ditto M. Nguyen N.Y. Boykins R. Unsworth E. Norcross M.A. J. Exp. Med. 1997; 186: 1865-1872Crossref PubMed Scopus (318) Google Scholar, S. De Meester I. Scharpé S. Lenaerts J.-P. P. P. Van Damme J. J. Immunol. 1998; 28: PubMed Scopus Google Scholar). However, RANTES(3–68) remained a for of the processing by CD26/DPP IV, activity against HIV-1 (9Proost P. De Meester I. Schols D. Struyf S. Lambeir A.-M. Wuyts A. Opdenakker G. De Clercq E. Scharpé S. Van Damme J. J. Biol. Chem. 1998; 273: 7222-7227Abstract Full Text Full Text PDF PubMed Scopus (238) Google D. P. Struyf S. Wuyts A. De Meester I. Scharpé S. Van Damme J. De Clercq E. 1998; PubMed Scopus Google Scholar, S. De Meester I. Scharpé S. Lenaerts J.-P. P. P. Van Damme J. J. Immunol. 1998; 28: PubMed Scopus Google Scholar). In MDC is a CD26/DPP IV substrate with an second cleavage in the of and MDC(5–69). of MDC by this dipeptidyl-peptidase in reduced biological activity on lymphocytes and dendritic cells, but not on monocytes. Thus, in addition to the of chemokine and chemokine receptor expression by and the NH2-terminal processing of MDC by CD26/DPP IV may have an important function in Th2 and dendritic cell its chemotactic and activity. and Wuyts for the and and for The chemokine cells were from through the and of of

References

29